BACKGROUND
IntegraGen was founded in 2000 on the basis of a locus identification technology for familial, polygenic diseases. The company rapidly built a portfolio of patents protecting its discoveries in the field of genetic predispositions.
DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY
Unique personalized sequencing services.
- Expert pharmacogenomics services (sequencing and genotyping) to research organizations on a CRO basis.
- Diagnostics: IntegraGen is developing panels of biomarkers likely to indicate an increased risk of disease onset (in autism and oncology), contributing to early molecular diagnosis and treatment.
CUSTOMER REFERENCES / COLLABORATIONS / HIGHLIGHTS
- Dec 2015: IntegraGen announced a collaboration with investigators from the FIRE-3 clinical trial to further study the oncology biomarker miR-31-3p, a microRNA whose expression has been shown to be associated with anti-EGFR e ect in patients with metastatic colorectal cancer.
- July 2015: IntegraGen and the Georges Pompidou European Hospital (HEGP) announced the signing of an agreement to develop the use of high-throughput sequencing techniques to improve the care of patients.
- June 2015: Results from two new studies exploring the role of the biomarker miR-31-3p in patients with metastatic colorectal cancer were presented during the 2015 ASCO Annual Meeting. The studies reported positive results on the association between miR-31-3p expression and clinical outcomes in metastatic colorectal cancer (mCRC) patients treated with panitumumab or cetuximab.
- March 2015: The Institut Pasteur and IntegraGen announced the signing of a partnership agreement making IntegraGen the operator of sequencing activities for the National Reference Centers (NRC) and microbiological collections of the Institut Pasteur.
COLLABORATIONS SOUGHT
In order to develop innovative and clinically useful diagnostic tools, IntegraGen controls the entire Genomic Diagnostics Services development chain:
- Technological leadership and command of state-of- the- art genomics, particularly command of technologies such as high bit-rate sequencing and genotyping and, in more general terms, all technologies relative to analysis of DNA and genetic cell material.
- Integration of academic or private research into the networks as partner or service providers.
- Establishment of networks of clinical practitioners specialized in targeted pathologies where the tools developed serve to improve patient care.
- Control of the biostatistics and bioinformatics validation aspects.
- Perfect knowledge of regulatory aspects.
- Access to reference laboratory markets in Europe and North America. IntegraGen’s vocation is to be number 1 in the genetic test field, thus contributing to diagnostics and improving care for targeted pathologies such as autism and certain forms of cancer.
